ClinicalTrials.gg
RecruitingNCT06304389BLUELIGHTVNSUpdated Nov 2, 2026

Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy

An interventional study of electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration and transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration in Refractory Epilepsy, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Nov 2, 2026Study completion movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Drug Resistant Epilepsy with a site in Belgium — 5 open to participants now, 6 under way, 1 of them phase 3. Drug Resistant Epilepsy · Belgium.

Planned enrollment
9th of 15
34 · median 40
Started
2023
with 1 other
No phase
8 of 17
4 open now
Registered
11th of 17
by date
Lead sponsor
4 of 17
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 11th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

5 of the 17 studies in Drug Resistant Epilepsy with a site in Belgium are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Drug Resistant Epilepsy with a site in Belgium, or all of them as a file.
02

Study summary

Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.

03

Conditions studied

  • Refractory Epilepsy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients:

VNS implanted since at least 3 months age >18-60 years; IQ >55 on Wechsler scale (normal status or mild cognitive impairment)

healthy participants aged between 18 and 35 years without any medical history (neurological / psychiatric disease)

Exclusion criteria

Exclusion criteria:

Patients:

other medical implanted devices than VNS, ocular diseases

Helthy participants:

medical implanted devices, cerebral trauma, ocular disease

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Patients with refractory epilepsy

    Patients will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.

    Other: electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration

  • Experimental
    Healthy subjects

    Subjects will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.

    Other: transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration

Interventions

  • Otherelectroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration

    Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.

  • Othertranscutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration

    Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.

06

What researchers measure

Primary outcomes

  1. Effect of blue light on VNS biomarkers

    Blue light increases VNS induced electroencephalogram desynchronisation in implanted patients

    Time frame: 4 years

  2. Effect of blue light on VNS biomarkers

    Blue light increases P300 amplitude in VNS implanted patients

    Time frame: 4 years

  3. Effect of blue light on VNS biomarkers

    Blue light increases VNS (or tVNS) induced pupil dilation (in patients \& healthy subjects).

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2023, 0 months.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's 0 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Dec 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
Mar 12, 2024
StartActual
Jul 1, 2023
Primary completionActual
Jul 1, 2023
CompletionEst.
Dec 2026was Apr 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Apr 2026→Dec 2026
Nov 2, 2026
Contact
Study contact changed: i•••@uclouvain.be · •••2917→i•••@uclouvain.be · •••2917. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Study completion Apr 2026→Dec 2026
    Contact Study contact changed: i•••@uclouvain.be · •••2917→i•••@uclouvain.be · •••2917. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06304389
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Jul 1, 2023
Primary completion
Jul 1, 2023
Completion
Dec 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Inci / cakiroglu
Contact
inci.cakiroglu@uclouvain.be
+32470612917

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion